United Therapeutics Corporation
UTHR
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exerciseā¦ read more
Healthcare
Biotechnology
26 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$564.81
Price-0.96%
-$5.46
1Y
Price
Market Cap
$24.754b
Large
Price/Earnings 3y Avg5y Avg
20.3x
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.+66.4%
EBITDA Margin+46.1%
Net Profit Margin+21.9%
Free Cash Flow Margin+66.4%
EBITDA Margin+46.1%
Net Profit Margin+21.9%
Free Cash Flow MarginRevenue
$3.183b
+10.6%
1y CAGR+18.2%
3y CAGR+17.3%
5y CAGREarnings
$1.335b
+11.7%
1y CAGR+22.8%
3y CAGR+30.3%
5y CAGREPS
$27.86
+13.1%
1y CAGR+23.2%
3y CAGR+29.7%
5y CAGRBook Value
$7.096b
$7.880b
Assets$783.800m
Liabilities-
DebtDebt to Assets
0.0%
-
Debt to EBITDAFree Cash Flow
$1.041b
-3.7%
1y CAGR+17.8%
3y CAGR+23.1%
5y CAGRNo items found.
Press Releases
Statements and updates from the company